Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.43 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | GBA3 | Q9H227 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.39 |
| ▸ | PRKCG | P05129 | 2/20 | 0.39 |
| ▸ | PRKCB | P05771 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioctylsulfane SCHEMBL28437640 | 0.97 | CES2 (0.54) | CES2THRBGMNNTP53POLB | |
| SCHEMBL226036 | 0.96 | CES2 (0.52) | CES2THRBGMNNTP53POLB | |
| Dioctylsulfane SCHEMBL28563294 | 0.94 | CES2 (0.52) | CES2THRBGMNNTP53POLB | |
| SCHEMBL7153595 | 0.93 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL867379 | 0.93 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL24362145 | 0.93 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL200291 | 0.93 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL198302 | 0.93 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL200549 | 0.93 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL199241 | 0.93 | THRB (0.57) | CES2THRBGMNNTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026273-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| CN-116019984-B | Single-layer hydrophilic coating, preparation system thereof and application thereof in hydrophilic modification of medical device surface | 上海发微医用材料有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116672515-A | Coating system comprising hydrophilic polymers, bilayer coating system, hydrophilic coating and use | 上海发微医用材料有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-115970070-B | Coating system comprising hydrophilic polymers, bilayer coating system, hydrophilic coating and use | 上海发微医用材料有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | claimed |
| CN-116390731-A | Combined cancer therapy with pentaaza macrocyclic complexes and hormonal therapeutic agents | 加莱拉实验室有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-18 | — | — | US | claimed |
| CN-116019984-A | Single-layer hydrophilic coating, preparation system thereof and application thereof in hydrophilic modification of medical device surface | 上海发微医用材料有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-115970070-A | Coating system comprising hydrophilic polymers, bilayer coating system, hydrophilic coating and use | 上海发微医用材料有限公司 | 2023-04-18 | — | — | CN | claimed |
| JP-H08505622-A | — | — | 1996-06-18 | — | — | JP | claimed |
| WO-1995031197-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | claimed |
| EP-0679155-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. | MONSANTO CO (US) | 1995-11-02 | — | — | EP | claimed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | claimed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | claimed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | claimed |
| US-5137857-A | Polymerization process | SHELL OIL COMPANY (US) | 1992-08-11 | — | — | US | claimed |
| US-5030712-A | Polymerization of CO/olefin with aryl phosphine sulfide | SHELL OIL COMPANY (US) | 1991-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | MC2R, GHRHR, GNRHR | CES2 4228/4885THRB 231/4885GMNN 772/4885 |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | HDAC1, HDAC8, SIRT3 | CES2 4568/4885THRB 168/4885GMNN 3505/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | CES2 1634/4885THRB 3832/4885GMNN 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.